What is the appropriate doxycycline dosing for symptomatic MRSA skin and soft‑tissue infection in adults and children?

Doxycycline Dosing for Symptomatic MRSA Skin and Soft‑Tissue Infections

For adults with symptomatic MRSA skin and soft‑tissue infections, prescribe doxycycline 100 mg orally twice daily for 5 days when purulent drainage or exudate is present; extend therapy only if warmth, tenderness, or erythema have not improved. 1

---

Adult Dosing

• Standard oral regimen: doxycycline 100 mg orally twice daily for 5 days. 1
• Severe infections requiring IV therapy: doxycycline 100 mg IV every 12 hours, combined with vancomycin 15–20 mg/kg IV every 8–12 hours to ensure adequate MRSA and streptococcal coverage in hospitalized patients. 1
• Treatment duration: 5 days is sufficient when clinical improvement (reduced warmth, tenderness, erythema, and absence of fever) is evident; extend only if symptoms persist. 1

---

Pediatric Dosing

• Children ≥8 years and <45 kg: doxycycline 2 mg/kg per dose orally every 12 hours (maximum 100 mg per dose) for 5 days. 1
• Children ≥8 years and ≥45 kg: use the adult dose of 100 mg orally twice daily. 1
• Absolute contraindication in children <8 years: doxycycline must never be used in this age group due to risk of permanent tooth discoloration and impaired bone growth. 1

---

Critical Requirement: Combination Therapy for Non‑Purulent Cellulitis

Doxycycline must be combined with a beta‑lactam (e.g., cephalexin 500 mg four times daily or amoxicillin 500 mg three times daily) when treating typical non‑purulent cellulitis, because tetracyclines lack reliable activity against beta‑hemolytic streptococci, the predominant pathogens in ~96% of cases. 1

• Monotherapy with doxycycline is appropriate only for purulent cellulitis (visible drainage or exudate) where MRSA coverage is the primary concern. 1
• Never use doxycycline alone for typical cellulitis; this misses streptococcal pathogens and represents a fundamental treatment error. 1

---

Indications for Adding MRSA Coverage (and When Doxycycline Is Appropriate)

Add MRSA‑active antibiotics such as doxycycline only when any of the following risk factors are present:

• Penetrating trauma or injection‑drug use. 1
• Visible purulent drainage or exudate at the infection site. 1
• Known MRSA colonization or prior MRSA infection. 1
• Systemic inflammatory response syndrome (fever >38°C, heart rate >90 bpm, respiratory rate >24 breaths/min). 1
• Lack of clinical response to beta‑lactam therapy after 48–72 hours. 1

In the absence of these factors, beta‑lactam monotherapy achieves ~96% clinical success, making routine MRSA coverage unnecessary and potentially harmful by promoting resistance. 1

---

Alternative MRSA‑Active Regimens

When MRSA coverage is required but doxycycline is contraindicated or not preferred:

• Clindamycin 300–450 mg orally every 6 hours provides single‑agent coverage for both streptococci and MRSA, but use only if local MRSA clindamycin resistance is <10%. 1, 2
• Trimethoprim‑sulfamethoxazole (TMP‑SMX) 1–2 double‑strength tablets twice daily plus a beta‑lactam ensures dual coverage; TMP‑SMX alone lacks reliable streptococcal activity. 1, 2
• Linezolid 600 mg orally twice daily is effective but more expensive; reserve for complicated cases or when other agents are unsuitable. 1, 2

---

Inpatient IV Regimens for Complicated MRSA Infections

For hospitalized patients with complicated skin and soft‑tissue infections:

• Vancomycin 15–20 mg/kg IV every 8–12 hours (target trough 15–20 mg/L) is first‑line therapy (A‑I evidence). 1, 2
• Linezolid 600 mg IV twice daily is an alternative with A‑I evidence, offering better lung penetration for MRSA pneumonia. 1, 2
• Daptomycin 4 mg/kg IV once daily is another A‑I option for complicated skin infections. 1, 2
• Clindamycin 600 mg IV every 8 hours may be used if local MRSA clindamycin resistance is <10% (A‑III evidence). 1, 2
• Treatment duration for complicated infections: 7–14 days, individualized based on clinical response. 1, 2

---

Absolute Contraindications to Doxycycline

• Children younger than 8 years: risk of permanent tooth discoloration and impaired bone growth. 1
• Pregnant women: pregnancy category D; fetal risk. 1

---

Common Pitfalls to Avoid

• Do not use doxycycline as monotherapy for typical non‑purulent cellulitis; this fails to cover streptococci in ~96% of cases and is a fundamental error. 1
• Do not add MRSA coverage reflexively for all cellulitis cases; MRSA is uncommon in typical non‑purulent cellulitis even in high‑prevalence settings. 1
• Do not automatically extend therapy to 7–10 days; extend only if warmth, tenderness, or erythema have not improved after 5 days. 1
• Do not prescribe doxycycline in children <8 years or pregnant women; use clindamycin or TMP‑SMX plus a beta‑lactam instead. 1

---

Adjunctive Measures

• Elevate the affected limb above heart level for at least 30 minutes three times daily to promote edema drainage and accelerate improvement. 1
• Incision and drainage is the primary treatment for any drainable abscess; antibiotics play only a subsidiary role. 1, 2
• Address predisposing conditions such as venous insufficiency, lymphedema, chronic edema, tinea pedis, and eczema to reduce recurrence risk. 1

---

Evidence Quality

The 2011 Infectious Diseases Society of America (IDSA) guidelines assign an A‑II level (strong recommendation, moderate‑quality evidence) to the use of doxycycline for outpatient MRSA coverage in skin and soft‑tissue infections. 1 High‑quality randomized controlled trial evidence shows 5‑day regimens are as effective as 10‑day regimens, achieving 98% clinical resolution at 14 days with no relapses by 28 days. 1